246 related articles for article (PubMed ID: 11779503)
1. Crystal structure of a phosphorylated Smad2. Recognition of phosphoserine by the MH2 domain and insights on Smad function in TGF-beta signaling.
Wu JW; Hu M; Chai J; Seoane J; Huse M; Li C; Rigotti DJ; Kyin S; Muir TW; Fairman R; Massagué J; Shi Y
Mol Cell; 2001 Dec; 8(6):1277-89. PubMed ID: 11779503
[TBL] [Abstract][Full Text] [Related]
2. Structural basis of Smad2 recognition by the Smad anchor for receptor activation.
Wu G; Chen YG; Ozdamar B; Gyuricza CA; Chong PA; Wrana JL; Massagué J; Shi Y
Science; 2000 Jan; 287(5450):92-7. PubMed ID: 10615055
[TBL] [Abstract][Full Text] [Related]
3. The N domain of Smad7 is essential for specific inhibition of transforming growth factor-beta signaling.
Hanyu A; Ishidou Y; Ebisawa T; Shimanuki T; Imamura T; Miyazono K
J Cell Biol; 2001 Dec; 155(6):1017-27. PubMed ID: 11739411
[TBL] [Abstract][Full Text] [Related]
4. The transcriptional co-activator P/CAF potentiates TGF-beta/Smad signaling.
Itoh S; Ericsson J; Nishikawa J; Heldin CH; ten Dijke P
Nucleic Acids Res; 2000 Nov; 28(21):4291-8. PubMed ID: 11058129
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure of a transcriptionally active Smad4 fragment.
Qin B; Lam SS; Lin K
Structure; 1999 Dec; 7(12):1493-503. PubMed ID: 10647180
[TBL] [Abstract][Full Text] [Related]
6. Structural basis of Smad1 activation by receptor kinase phosphorylation.
Qin BY; Chacko BM; Lam SS; de Caestecker MP; Correia JJ; Lin K
Mol Cell; 2001 Dec; 8(6):1303-12. PubMed ID: 11779505
[TBL] [Abstract][Full Text] [Related]
7. Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway.
Xu J; Attisano L
Proc Natl Acad Sci U S A; 2000 Apr; 97(9):4820-5. PubMed ID: 10781087
[TBL] [Abstract][Full Text] [Related]
8. Roles for the MH2 domain of Smad7 in the specific inhibition of transforming growth factor-beta superfamily signaling.
Mochizuki T; Miyazaki H; Hara T; Furuya T; Imamura T; Watabe T; Miyazono K
J Biol Chem; 2004 Jul; 279(30):31568-74. PubMed ID: 15148321
[TBL] [Abstract][Full Text] [Related]
9. Tumor-derived C-terminal mutations of Smad4 with decreased DNA binding activity and enhanced intramolecular interaction.
Kuang C; Chen Y
Oncogene; 2004 Feb; 23(5):1021-9. PubMed ID: 14647410
[TBL] [Abstract][Full Text] [Related]
10. Functional conservation of Schistosoma mansoni Smads in TGF-beta signaling.
Beall MJ; McGonigle S; Pearce EJ
Mol Biochem Parasitol; 2000 Nov; 111(1):131-42. PubMed ID: 11087923
[TBL] [Abstract][Full Text] [Related]
11. Linking Smads and transcriptional activation.
Inman GJ
Biochem J; 2005 Feb; 386(Pt 1):e1-e3. PubMed ID: 15702493
[TBL] [Abstract][Full Text] [Related]
12. The TGF beta receptor activation process: an inhibitor- to substrate-binding switch.
Huse M; Muir TW; Xu L; Chen YG; Kuriyan J; Massagué J
Mol Cell; 2001 Sep; 8(3):671-82. PubMed ID: 11583628
[TBL] [Abstract][Full Text] [Related]
13. The L3 loop and C-terminal phosphorylation jointly define Smad protein trimerization.
Chacko BM; Qin B; Correia JJ; Lam SS; de Caestecker MP; Lin K
Nat Struct Biol; 2001 Mar; 8(3):248-53. PubMed ID: 11224571
[TBL] [Abstract][Full Text] [Related]
14. The transforming growth factor-beta/SMAD signaling pathway is present and functional in human mesangial cells.
Poncelet AC; de Caestecker MP; Schnaper HW
Kidney Int; 1999 Oct; 56(4):1354-65. PubMed ID: 10504488
[TBL] [Abstract][Full Text] [Related]
15. TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4.
Nakao A; Imamura T; Souchelnytskyi S; Kawabata M; Ishisaki A; Oeda E; Tamaki K; Hanai J; Heldin CH; Miyazono K; ten Dijke P
EMBO J; 1997 Sep; 16(17):5353-62. PubMed ID: 9311995
[TBL] [Abstract][Full Text] [Related]
16. Differential ubiquitination defines the functional status of the tumor suppressor Smad4.
Morén A; Hellman U; Inada Y; Imamura T; Heldin CH; Moustakas A
J Biol Chem; 2003 Aug; 278(35):33571-82. PubMed ID: 12794086
[TBL] [Abstract][Full Text] [Related]
17. Structural mechanism of Smad4 recognition by the nuclear oncoprotein Ski: insights on Ski-mediated repression of TGF-beta signaling.
Wu JW; Krawitz AR; Chai J; Li W; Zhang F; Luo K; Shi Y
Cell; 2002 Nov; 111(3):357-67. PubMed ID: 12419246
[TBL] [Abstract][Full Text] [Related]
18. Two short segments of Smad3 are important for specific interaction of Smad3 with c-Ski and SnoN.
Mizuide M; Hara T; Furuya T; Takeda M; Kusanagi K; Inada Y; Mori M; Imamura T; Miyazawa K; Miyazono K
J Biol Chem; 2003 Jan; 278(1):531-6. PubMed ID: 12426322
[TBL] [Abstract][Full Text] [Related]
19. Semisynthesis of phosphovariants of Smad2 reveals a substrate preference of the activated T beta RI kinase.
Ottesen JJ; Huse M; Sekedat MD; Muir TW
Biochemistry; 2004 May; 43(19):5698-706. PubMed ID: 15134444
[TBL] [Abstract][Full Text] [Related]
20. Structural basis of heteromeric smad protein assembly in TGF-beta signaling.
Chacko BM; Qin BY; Tiwari A; Shi G; Lam S; Hayward LJ; De Caestecker M; Lin K
Mol Cell; 2004 Sep; 15(5):813-23. PubMed ID: 15350224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
